Risk factors for primary sclerosing cholangitis

Background & Aims Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease of unknown cause, but strongly associated with inflammatory bowel disease (IBD). Potential risk factors triggering PSC have never been studied on a population level. The aim of this study was to eva...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2016-01, Vol.36 (1), p.84-91
Main Authors: Boonstra, Kirsten, de Vries, Elisabeth M. G., van Geloven, Nan, van Erpecum, Karel J., Spanier, Marcel, Poen, Alexander C., van Nieuwkerk, Carin M., Witteman, Ben J., Tuynman, Hans A., Naber, Anton H., Kingma, Paul J., Beuers, Ulrich, Ponsioen, Cyriel Y.
Format: Article
Language:English
Subjects:
Adult
appendectomy
Appendectomy - statistics & numerical data
Case-Control Studies
Cholangitis, Sclerosing - epidemiology
Demography
Female
Humans
Inflammatory Bowel Diseases - epidemiology
Male
Middle Aged
Netherlands - epidemiology
primary sclerosing cholangitis
Protective Factors
Risk Factors
smoking
Smoking - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Primary sclerosing cholangitis (PSC) is a progressive cholestatic liver disease of unknown cause, but strongly associated with inflammatory bowel disease (IBD). Potential risk factors triggering PSC have never been studied on a population level. The aim of this study was to evaluate smoking, appendectomy, family history and geographical distribution in a population‐based cohort of PSC patients, as compared to IBD control patients and healthy controls (HC). Methods For this case–control study 343 PSC patients, 370 IBD controls and 232 HC's living in a geographically defined area in the Netherlands filled‐out a questionnaire concerning smoking, appendectomy and family history of IBD and autoimmune liver diseases. Results Smoking was associated with a lower risk of developing PSC in PSC‐ulcerative colitis (UC) patients (adjusted OR 0.21; 95% CI 0.12–0.34; P 
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.12894